 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Foundations of Targeted Cancer Therapy

Introduction to Targeted Therapies

Biomarkers and Molecular Targets

Small Molecule Kinase Inhibitors

Kinases and Small Molecule Inhibitors

EGFR Inhibitors

BCR-ABL Inhibitors

BRAF Inhibitors

Monoclonal Antibodies in Targeted Therapy

Mechanisms of Monoclonal Antibodies

Examples of Therapeutic Monoclonal Antibodies

Synthetic Lethality and PARP Inhibitors

The Principle of Synthetic Lethality

PARP Inhibitors and DNA Repair Defects

Primary and Acquired Drug Resistance

Understanding Primary and Acquired Resistance

Target Alterations and Gatekeeper Mutations

Bypass Signaling and Pathway Reactivation

Additional Resistance Mechanisms and Treatment Strategies

Clinical Integration and Review

Applying Targeted Therapy Concepts to Clinical Cases

Key Concepts Summary

Quiz

Question 1: Which category of targeted therapy is designed to bind an extracellular or cell-surface target?

Question 2: How do EGFR small molecule inhibitors generally reduce tumor-cell signaling?

Question 3: What is the synthetic-lethality rationale for using PARP inhibitors in tumors with BRCA-associated homologous recombination repair defects?

Question 4: Which statement best distinguishes primary resistance from acquired resistance?

Question 5: How can a gatekeeper mutation contribute to resistance to a kinase inhibitor?

Survey and Feedback

Course Feedback Survey

Welcome to "Targeted Therapies: Mechanisms of Action and Drug Resistance," a comprehensive online course designed to deepen your understanding of modern precision oncology. As cancer treatment shifts from conventional cytotoxic chemotherapy to highly specific molecular interventions, healthcare professionals and researchers must stay at the forefront of these advancements.

Welcome to "Targeted Therapies: Mechanisms of Action and Drug Resistance," a comprehensive online course designed to deepen your understanding of modern precision oncology. As cancer treatment shifts from conventional cytotoxic chemotherapy to highly specific molecular interventions, healthcare professionals and researchers must stay at the forefront of these advancements. This course explores the foundational principles of targeted cancer therapies, focusing on how these innovative treatments interfere with specific molecular features that drive tumor growth and survival. Throughout this program, you will dive into the mechanisms of small molecule kinase inhibitors, monoclonal antibodies, and synthetic-lethality approaches, including PARP inhibitors. We will examine critical biomarkers, such as EGFR, BCR-ABL, BRAF, and BRCA, and how they guide personalized treatment selection. Furthermore, the course tackles one of the most significant challenges in oncology today: drug resistance. You will learn to differentiate between primary and acquired resistance, understand the role of gatekeeper mutations and bypass signaling, and explore clinical strategies to overcome these hurdles. By integrating molecular biology with clinical case scenarios, this course bridges the gap between bench research and bedside application. Whether you are a medical student, an oncology practitioner, or a cancer researcher, this course will equip you with the knowledge to navigate the complex landscape of targeted therapies and improve patient outcomes.

Targeted Therapies: Mechanisms of Action and Drug Resistance

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The advent of targeted cancer therapies has fundamentally transformed the landscape of oncology by shifting the treatment paradigm from broad cytotoxic approaches to precision medicine. This course provides a comprehensive examination of the mechanisms of action underlying these advanced therapeutics, focusing on how they exploit specific molecular vulnerabilities to inhibit cancer cell growth and survival. Throughout the curriculum, learners will explore the foundational principles of biomarker-guided treatment selection and delve into the distinct pharmacological categories of targeted agents. Key areas of study include the intracellular modulation achieved by small molecule kinase inhibitors—such as those targeting EGFR, BCR-ABL, and BRAF—as well as the extracellular mechanisms of monoclonal antibodies and the exploitation of DNA repair defects through the principle of synthetic lethality using PARP inhibitors.</p>

<p>Despite the profound clinical efficacy of targeted therapies, the emergence of drug resistance remains a critical challenge in sustained cancer management. To address this complex issue, the course systematically investigates the biological underpinnings of both primary and acquired resistance. Learners will analyze specific resistance mechanisms, including target-site alterations, gatekeeper mutations, bypass signaling, and pathway reactivation, which allow tumors to evade therapeutic intervention. By integrating these molecular concepts with clinical case scenarios, the curriculum equips professionals with the analytical skills necessary to interpret tumor progression, evaluate the rationale for combination therapies, and understand the vital role of ongoing molecular profiling in optimizing personalized patient care.</p>
        </div>
    </div>
</div>
